WO2010009892A3 - Compositions for the treatment of pain and/or inflamation - Google Patents

Compositions for the treatment of pain and/or inflamation Download PDF

Info

Publication number
WO2010009892A3
WO2010009892A3 PCT/EP2009/005381 EP2009005381W WO2010009892A3 WO 2010009892 A3 WO2010009892 A3 WO 2010009892A3 EP 2009005381 W EP2009005381 W EP 2009005381W WO 2010009892 A3 WO2010009892 A3 WO 2010009892A3
Authority
WO
WIPO (PCT)
Prior art keywords
pain
treatment
compositions
inflamation
cosmetically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/005381
Other languages
French (fr)
Other versions
WO2010009892A8 (en
WO2010009892A2 (en
Inventor
Cristina CARRENO SERRAÏMA
Wim Van Den Nest
Antonio Ferrer Montiel
Maria Camprubi Robes
Jimena Fernandez Carneado
Berta Ponsati Obliols
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DiverDrugs SL
BCN Peptides SA
Original Assignee
DiverDrugs SL
BCN Peptides SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US13/055,598 priority Critical patent/US20110206752A1/en
Priority to JP2011519085A priority patent/JP5920916B2/en
Priority to DK09777419.4T priority patent/DK2318033T3/en
Priority to CN200980137382.XA priority patent/CN102164610B/en
Priority to ES09777419T priority patent/ES2714357T3/en
Priority to AU2009273471A priority patent/AU2009273471C1/en
Priority to LTEP09777419.4T priority patent/LT2318033T/en
Priority to SI200931917T priority patent/SI2318033T1/en
Priority to RU2011105280/04A priority patent/RU2515054C2/en
Priority to BRPI0911743-1A priority patent/BRPI0911743B1/en
Priority to HRP20190059TT priority patent/HRP20190059T1/en
Priority to EP09777419.4A priority patent/EP2318033B8/en
Application filed by DiverDrugs SL, BCN Peptides SA filed Critical DiverDrugs SL
Priority to PL09777419T priority patent/PL2318033T3/en
Priority to MX2011000868A priority patent/MX2011000868A/en
Priority to CA2731880A priority patent/CA2731880C/en
Publication of WO2010009892A2 publication Critical patent/WO2010009892A2/en
Publication of WO2010009892A3 publication Critical patent/WO2010009892A3/en
Priority to IL210810A priority patent/IL210810B/en
Anticipated expiration legal-status Critical
Publication of WO2010009892A8 publication Critical patent/WO2010009892A8/en
Priority to US16/233,378 priority patent/US20190184054A1/en
Priority to CY191100041T priority patent/CY1121125T1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Birds (AREA)
  • Materials Engineering (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compositions for the treatment of pain and/or inflammation comprising at least one peptide with the general formula (I) R1-AA-R2 , its stereoisomers, mixtures thereof, and its cosmetically and pharmaceutically acceptable salts. Peptide with general formula (I), its stereoisomers, mixtures thereof, and its cosmetically and pharmaceutically acceptable salts for the treatment of pain and/or inflammation.
PCT/EP2009/005381 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflamation Ceased WO2010009892A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
HRP20190059TT HRP20190059T1 (en) 2008-07-24 2009-07-24 PREPARATIONS FOR TREATMENT OF PAIN AND / OR INFLAMMATION
DK09777419.4T DK2318033T3 (en) 2008-07-24 2009-07-24 COMPOSITIONS FOR TREATMENT OF PAIN AND / OR INFLAMMATION
CN200980137382.XA CN102164610B (en) 2008-07-24 2009-07-24 Compositions for treating pain and/or inflammation
ES09777419T ES2714357T3 (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and / or inflammation
AU2009273471A AU2009273471C1 (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflammation
JP2011519085A JP5920916B2 (en) 2008-07-24 2009-07-24 Composition for the treatment of pain and / or inflammation
SI200931917T SI2318033T1 (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflammation
RU2011105280/04A RU2515054C2 (en) 2008-07-24 2009-07-24 Composition for treating pain and/or inflammation
BRPI0911743-1A BRPI0911743B1 (en) 2008-07-24 2009-07-24 USE OF A PEPTIDE
EP09777419.4A EP2318033B8 (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflammation
LTEP09777419.4T LT2318033T (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflammation
US13/055,598 US20110206752A1 (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflamation
PL09777419T PL2318033T3 (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflamation
MX2011000868A MX2011000868A (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflamation.
CA2731880A CA2731880C (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflammation comprising snap-25 peptides
IL210810A IL210810B (en) 2008-07-24 2011-01-23 Peptides for the treatment of pain and/or inflammation
US16/233,378 US20190184054A1 (en) 2008-07-24 2018-12-27 Compositions for the treatment of pain and/or inflammation
CY191100041T CY1121125T1 (en) 2008-07-24 2019-01-15 COMPOSITIONS FOR THE TREATMENT OF PAIN AND / OR INFLAMMATION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200802210 2008-07-24
ES200802210A ES2356883B1 (en) 2008-07-24 2008-07-24 COMPOSITION FOR THE TREATMENT OF PAIN AND / OR INFLAMMATION.

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/055,598 A-371-Of-International US20110206752A1 (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflamation
US16/233,378 Continuation US20190184054A1 (en) 2008-07-24 2018-12-27 Compositions for the treatment of pain and/or inflammation

Publications (3)

Publication Number Publication Date
WO2010009892A2 WO2010009892A2 (en) 2010-01-28
WO2010009892A3 true WO2010009892A3 (en) 2010-05-14
WO2010009892A8 WO2010009892A8 (en) 2011-02-24

Family

ID=41462205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/005381 Ceased WO2010009892A2 (en) 2008-07-24 2009-07-24 Compositions for the treatment of pain and/or inflamation

Country Status (24)

Country Link
US (2) US20110206752A1 (en)
EP (1) EP2318033B8 (en)
JP (1) JP5920916B2 (en)
KR (1) KR20110056491A (en)
CN (1) CN102164610B (en)
AR (1) AR072610A1 (en)
AU (1) AU2009273471C1 (en)
BR (1) BRPI0911743B1 (en)
CA (1) CA2731880C (en)
CY (1) CY1121125T1 (en)
DK (1) DK2318033T3 (en)
ES (2) ES2356883B1 (en)
HR (1) HRP20190059T1 (en)
HU (1) HUE042083T2 (en)
IL (1) IL210810B (en)
LT (1) LT2318033T (en)
MX (1) MX2011000868A (en)
PL (1) PL2318033T3 (en)
PT (1) PT2318033T (en)
RU (1) RU2515054C2 (en)
SG (1) SG192548A1 (en)
SI (1) SI2318033T1 (en)
TR (1) TR201900542T4 (en)
WO (1) WO2010009892A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961510A1 (en) * 2010-06-17 2011-12-23 Oreal USE AS A TREATMENT AGENT FOR HUMAN PERSPIRATION; NOVEL AMINO ACID DERIVATIVES; COMPOSITIONS CONTAINING THEM
ES2385683B1 (en) * 2010-10-18 2013-10-07 Bcn Peptides, S.A. COMPOSITIONS FOR THE TREATMENT OF PAIN AND / OR INFLAMMATION.
EP3248609B1 (en) 2011-10-28 2019-10-16 NeoStrata Company, Inc. N-acyldipeptide derivatives and their uses
EP2802337B2 (en) 2011-11-07 2021-01-20 Feng Tian Peptide-based compounds as inhibitors of neurotransmitter secretion
US9687669B2 (en) 2011-11-09 2017-06-27 John Stephan Wearable light therapy apparatus
CA2859915A1 (en) * 2012-01-03 2013-07-11 Ruey J. Yu N-acylpeptide derivatives and their uses
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
JP6470678B2 (en) 2012-04-13 2019-02-13 ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド Compound (II) that inhibits neuronal exocytosis
EP2649984A1 (en) * 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
DE102014007423A1 (en) * 2014-05-22 2015-11-26 Bitop Ag Composition for the treatment of the eye
RU2580280C2 (en) * 2014-07-08 2016-04-10 Общество с ограниченной ответственностью "НИТРОЗДРАВ" Composition for local application for reduction or relief of pain syndrome
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
US20190083809A1 (en) 2016-07-27 2019-03-21 Z2020, Llc Componentry and devices for light therapy delivery and methods related thereto
WO2018102508A1 (en) * 2016-11-30 2018-06-07 Lubrizol Advanced Materials, Inc. Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes
WO2019054822A1 (en) * 2017-09-18 2019-03-21 애니젠 주식회사 Active substance-hexapeptide complex and cosmetic composition containing same
JP2020536955A (en) 2017-10-06 2020-12-17 ファウンドリー セラピューティクス， インコーポレイテッド Implantable depot for controlled release of therapeutic agent
EP3737433A1 (en) 2018-01-08 2020-11-18 Foundry Therapeutics, Inc. Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents
WO2019221853A1 (en) 2018-05-12 2019-11-21 Foundry Therapeutics, Inc. Implantable depots for the controlled release of therapeutic agents
CN112165955A (en) 2018-05-21 2021-01-01 益普生生物制药有限公司 Inhibiting allodynia caused by bone cancer
US12377035B2 (en) 2018-06-13 2025-08-05 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO—A.C.R.A.F. S.p.A. Peptides for inhibiting cholinergic calcitonin gene-related peptide (CGRP) and acetylcholine (ACH) release or inhibiting sensitization-mediated by TRPV1-mediated excitability in sensory neurons and methods of use thereof
EP3843710A1 (en) 2018-08-28 2021-07-07 Foundry Therapeutics, Inc. Polymer implants
SG11202109937UA (en) 2019-03-14 2021-10-28 Om Pharma Sa Stable bacterial extracts as pharmaceuticals
EP3988092B1 (en) 2019-06-24 2026-01-28 Shenzhen Fangshengtai Medical Technology Co., Ltd. Oxovanadium complexes for use in the treatment of pain
CN116970034A (en) * 2022-10-14 2023-10-31 深圳市维琪科技股份有限公司 Synthetic peptides, compositions and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034620A1 (en) * 1996-03-18 1997-09-25 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
WO2001078760A2 (en) * 2000-04-14 2001-10-25 Allergan, Inc. Method for treating pain by peripheral administration of a neurotoxin
WO2002089834A1 (en) * 2001-05-04 2002-11-14 Imperial College Innovations Limited Bont/e or snap-25e for treating botulinum toxin a or c1 poisoning and inhibiting muscle contraction
WO2007093807A2 (en) * 2006-02-15 2007-08-23 Morvus Technology Limited Apoptosis methods, genes and proteins
KR20090041066A (en) * 2007-10-23 2009-04-28 성균관대학교산학협력단 Synthetic Peptides Regulate Neurotransmitter Release

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
EP1086702B1 (en) * 1994-05-09 2005-04-13 BINDER, William J. Presynaptic neurotoxins for treatment of migraine headache
ES2160485B1 (en) * 1999-04-23 2002-05-16 Lipotec Sa INHIBITING PEPTIDES OF NEURONAL EXOCITOSIS, COSMETIC AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6641820B1 (en) * 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6500436B2 (en) * 2000-01-19 2002-12-31 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US6565870B1 (en) * 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US7255866B2 (en) * 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7071167B2 (en) * 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
SG160358A1 (en) * 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of an oligopeptide
CN101374860A (en) * 2005-12-23 2009-02-25 技术转让合伙人公司 Synthetic peptides useful as neurotransmitter secretion inhibitors and muscle relaxation inducers
FR2902341B1 (en) * 2006-06-16 2011-02-25 Scras THERAPEUTIC USE SIMULTANEOUS, SEPARATE OR SPREAD IN THE TIME OF AT LEAST ONE BOTULINUM NEUROTOXIN, AND AT LEAST ONE OPIACEOUS DERIVATIVE
ES2322882B1 (en) * 2006-10-25 2010-04-22 Lipotec Sa INHIBITING PEPTIDES OF NEURONAL EXOCITOSIS.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034620A1 (en) * 1996-03-18 1997-09-25 The Regents Of The University Of California Peptide inhibitors of neurotransmitter secretion by neuronal cells
WO2001078760A2 (en) * 2000-04-14 2001-10-25 Allergan, Inc. Method for treating pain by peripheral administration of a neurotoxin
WO2002089834A1 (en) * 2001-05-04 2002-11-14 Imperial College Innovations Limited Bont/e or snap-25e for treating botulinum toxin a or c1 poisoning and inhibiting muscle contraction
WO2007093807A2 (en) * 2006-02-15 2007-08-23 Morvus Technology Limited Apoptosis methods, genes and proteins
KR20090041066A (en) * 2007-10-23 2009-04-28 성균관대학교산학협력단 Synthetic Peptides Regulate Neurotransmitter Release

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200951, Derwent World Patents Index; AN 2009-J28980, XP002573254 *

Also Published As

Publication number Publication date
TR201900542T4 (en) 2019-02-21
US20190184054A1 (en) 2019-06-20
SI2318033T1 (en) 2019-02-28
ES2356883B1 (en) 2012-02-22
MX2011000868A (en) 2011-06-09
RU2515054C2 (en) 2014-05-10
RU2011105280A (en) 2012-08-27
AU2009273471A1 (en) 2010-01-28
ES2356883A1 (en) 2011-04-14
CA2731880C (en) 2016-12-13
PL2318033T3 (en) 2019-04-30
SG192548A1 (en) 2013-08-30
EP2318033A2 (en) 2011-05-11
KR20110056491A (en) 2011-05-30
BRPI0911743A2 (en) 2015-07-07
HRP20190059T1 (en) 2019-03-08
LT2318033T (en) 2019-02-11
AR072610A1 (en) 2010-09-08
US20110206752A1 (en) 2011-08-25
CN102164610A (en) 2011-08-24
BRPI0911743B1 (en) 2021-11-16
HUE042083T2 (en) 2019-06-28
JP2011528678A (en) 2011-11-24
WO2010009892A8 (en) 2011-02-24
CA2731880A1 (en) 2010-01-28
IL210810A0 (en) 2011-04-28
IL210810B (en) 2018-04-30
EP2318033B8 (en) 2019-02-27
DK2318033T3 (en) 2019-02-04
WO2010009892A2 (en) 2010-01-28
EP2318033B1 (en) 2018-10-17
ES2714357T3 (en) 2019-05-28
PT2318033T (en) 2019-01-24
CY1121125T1 (en) 2019-12-11
JP5920916B2 (en) 2016-05-18
AU2009273471C1 (en) 2014-08-21
CN102164610B (en) 2014-04-09
AU2009273471B2 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
WO2010009892A8 (en) Compositions for the treatment of pain and/or inflamation
WO2007135527A3 (en) Benzimidazolyl compounds
WO2008019357A3 (en) Indole compounds
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
UA92637C2 (en) Pyridine[3,4-b]pyrazinones
WO2009105513A3 (en) Novel compounds and methods for therapy
WO2004072031A8 (en) Phenylacetamides and their use as glucokinase modulators
MX2010005889A (en) Novel thiophene derivatives.
TW200605870A (en) Topical methadone compositions and methods for using the same
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
EP2452935A3 (en) Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
WO2009049184A9 (en) Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
WO2009075882A3 (en) Impaired wound healing compositions and treatments
TN2010000074A1 (en) Cyclic depsipeptides
EP3330252A3 (en) Isoprenyl compounds and methods thereof
WO2007143557A3 (en) Compounds and methods for treating mammalian gastrointestinal parasitic infections
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
WO2008092580A3 (en) Synergistic fungicidal combinations comprising formononetin
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
WO2008071961A8 (en) 2-quinolinone and 2-quinoxalinone- derivatives and their use as antibacterial agents
WO2009106599A3 (en) Substituted piperidines as therapeutic compounds
TWI372047B (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
WO2008050157A3 (en) Ozonated oil formulations
WO2009061445A3 (en) Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction
PL1750744T3 (en) Medicament for the treatment of fungal infections, particularly aspergillosis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980137382.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2009777419

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011519085

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/000868

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2731880

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009273471

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009273471

Country of ref document: AU

Date of ref document: 20090724

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1199/DELNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20117004108

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011105280

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 13055598

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0911743

Country of ref document: BR

Free format text: EM ADITAMENTO A EXIGENCIA PUBLICADA NA RPI 2185 DE 20/11/2012. SOLICITA-SE QUE O DEPOSITANTE APRESENTE O CODIGO ALFANUMERICO E AS DECLARACOES REFERENTES AOS CD APRESENTADOS NA PETICAO 018120043530 DE 26/11/2012.

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0911743

Country of ref document: BR

Free format text: EM ADITAMENTO A EXIGENCIA PUBLICADA NA RPI 2185 DE 20/11/2012 SOLICITA-SE QUE SEJAM APRESENTADOS NOVOS CDS/DVDS E SUAS RESPECTIVAS DECLARACOES E CODIGO ALFANUMERICO, POIS O CONTEUDO DO ARQUIVO DA LISTAGEM DE SEQUEENCIA NAO FOI APRESENTADO NO PADRAO OMPI ST.25.

ENP Entry into the national phase

Ref document number: PI0911743

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110124